home / stock / omga / omga articles

OMGA Articles, Omega Therapeutics Inc. - From 11/02/23

Stock Information
Company Name: Omega Therapeutics Inc.
Stock Symbol: OMGA
Market: NASDAQ
Website: omegatherapeutics.com
Menu
OMGA OMGA Quote OMGA Short OMGA News OMGA Articles OMGA Message Board
Get OMGA Alerts

News, Short Squeeze, Breakout and More Instantly...
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session | Benzinga

Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholder...
Omega Therapeutics Announces Two Poster Presentations on Liver Inflammation and Fibrosis at AASLD's The Liver Meeting® 2023 | Benzinga

CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pio...

Top 4 Health Care Stocks That Are Preparing To Pump This Quarter | Benzinga

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...

Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | Benzinga

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pio...
Omega Therapeutics' Cancer Program Shows Encouraging Anti Tumor Activity In Liver Cancer | Benzinga

Omega Therapeutics Inc (NASDAQ: OMGA) announced preliminary data from the initial two dose level cohorts (n=8) from Part 1 of its Phase 1/2 MY...

Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial | Benzinga

All 8 patients treated with OTX-2002 in initial two cohorts achieved highly specific on-target genomic engagement, intended epigenetic state chang...

Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26 | Benzinga

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pi...
Omega Therapeutics to Participate in Two Upcoming Investor Conferences | Benzinga

CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pi...

Omega Therapeutics Announces Updates to its Board of Directors | Benzinga

Chris Schade to Assume Role of Chairman of the Board, Succeeding Noubar Afeyan, Ph.D. Michelle C. Werner, CEO of Alltrna, Appointed to Board of D...

Previous 10 Next 10